Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer

Jen-Jane Liu, Daphne Y. Lichtensztajn, Scarlett Lin Gomez, Weiva Sieh, Benjamin I. Chung, Iona Cheng, James D. Brooks

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Based on revisions of Gleason scoring in 2005, it has been reported that nodal metastases at radical prostatectomy in Gleason 3+3=6 (GS6) prostate cancer are extremely rare, and that GS6 cancers with nodal metastases are invariably upgraded upon review by academic urological pathologists. We analysed the prevalence and determinants of nodal metastases in a national sample of patients with GS6 cancer. We utilised the SEER database to identify patients diagnosed with GS6 prostate cancer during 2004-2010 who had radical prostatectomy and ≥1 lymph node(s) examined. We calculated the prevalence of nodal metastases and constructed a multivariable logistic regression model to identify factors associated with nodal metastases. Among 21,960 patients, the prevalence of nodal metastases was 0.48%. Older age, preoperative PSA ≥10 ng/mL, and advanced stage were positively associated with nodal metastases. Lymph node metastases in GS6 cancer are more prevalent in a nationwide population compared to academic centres. Revised guidelines for Gleason scoring have made GS6 cancer a more homogeneously indolent disease, which may be relevant in the era of active surveillance. We submit that lymph node metastases in GS6 cancer be used as a proxy for adherence to the 2005 ISUP consensus on Gleason grading.

Original languageEnglish (US)
Pages (from-to)306-310
Number of pages5
JournalPathology
Volume46
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Neoplasm Grading
Prostatic Neoplasms
Lymph Nodes
Neoplasm Metastasis
Neoplasms
Prostatectomy
Logistic Models
Proxy
Databases
Guidelines

Keywords

  • Gleason score
  • Lymph node metastasis
  • Prostatic neoplasms
  • SEER program

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Liu, J-J., Lichtensztajn, D. Y., Gomez, S. L., Sieh, W., Chung, B. I., Cheng, I., & Brooks, J. D. (2014). Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer. Pathology, 46(4), 306-310. https://doi.org/10.1097/PAT.0000000000000097

Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer. / Liu, Jen-Jane; Lichtensztajn, Daphne Y.; Gomez, Scarlett Lin; Sieh, Weiva; Chung, Benjamin I.; Cheng, Iona; Brooks, James D.

In: Pathology, Vol. 46, No. 4, 2014, p. 306-310.

Research output: Contribution to journalArticle

Liu, J-J, Lichtensztajn, DY, Gomez, SL, Sieh, W, Chung, BI, Cheng, I & Brooks, JD 2014, 'Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer', Pathology, vol. 46, no. 4, pp. 306-310. https://doi.org/10.1097/PAT.0000000000000097
Liu, Jen-Jane ; Lichtensztajn, Daphne Y. ; Gomez, Scarlett Lin ; Sieh, Weiva ; Chung, Benjamin I. ; Cheng, Iona ; Brooks, James D. / Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer. In: Pathology. 2014 ; Vol. 46, No. 4. pp. 306-310.
@article{3b43681d853b4460984c9e1bf7f8a8de,
title = "Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer",
abstract = "Based on revisions of Gleason scoring in 2005, it has been reported that nodal metastases at radical prostatectomy in Gleason 3+3=6 (GS6) prostate cancer are extremely rare, and that GS6 cancers with nodal metastases are invariably upgraded upon review by academic urological pathologists. We analysed the prevalence and determinants of nodal metastases in a national sample of patients with GS6 cancer. We utilised the SEER database to identify patients diagnosed with GS6 prostate cancer during 2004-2010 who had radical prostatectomy and ≥1 lymph node(s) examined. We calculated the prevalence of nodal metastases and constructed a multivariable logistic regression model to identify factors associated with nodal metastases. Among 21,960 patients, the prevalence of nodal metastases was 0.48{\%}. Older age, preoperative PSA ≥10 ng/mL, and advanced stage were positively associated with nodal metastases. Lymph node metastases in GS6 cancer are more prevalent in a nationwide population compared to academic centres. Revised guidelines for Gleason scoring have made GS6 cancer a more homogeneously indolent disease, which may be relevant in the era of active surveillance. We submit that lymph node metastases in GS6 cancer be used as a proxy for adherence to the 2005 ISUP consensus on Gleason grading.",
keywords = "Gleason score, Lymph node metastasis, Prostatic neoplasms, SEER program",
author = "Jen-Jane Liu and Lichtensztajn, {Daphne Y.} and Gomez, {Scarlett Lin} and Weiva Sieh and Chung, {Benjamin I.} and Iona Cheng and Brooks, {James D.}",
year = "2014",
doi = "10.1097/PAT.0000000000000097",
language = "English (US)",
volume = "46",
pages = "306--310",
journal = "Pathology",
issn = "0031-3025",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Nationwide prevalence of lymph node metastases in Gleason score 3+3=6 prostate cancer

AU - Liu, Jen-Jane

AU - Lichtensztajn, Daphne Y.

AU - Gomez, Scarlett Lin

AU - Sieh, Weiva

AU - Chung, Benjamin I.

AU - Cheng, Iona

AU - Brooks, James D.

PY - 2014

Y1 - 2014

N2 - Based on revisions of Gleason scoring in 2005, it has been reported that nodal metastases at radical prostatectomy in Gleason 3+3=6 (GS6) prostate cancer are extremely rare, and that GS6 cancers with nodal metastases are invariably upgraded upon review by academic urological pathologists. We analysed the prevalence and determinants of nodal metastases in a national sample of patients with GS6 cancer. We utilised the SEER database to identify patients diagnosed with GS6 prostate cancer during 2004-2010 who had radical prostatectomy and ≥1 lymph node(s) examined. We calculated the prevalence of nodal metastases and constructed a multivariable logistic regression model to identify factors associated with nodal metastases. Among 21,960 patients, the prevalence of nodal metastases was 0.48%. Older age, preoperative PSA ≥10 ng/mL, and advanced stage were positively associated with nodal metastases. Lymph node metastases in GS6 cancer are more prevalent in a nationwide population compared to academic centres. Revised guidelines for Gleason scoring have made GS6 cancer a more homogeneously indolent disease, which may be relevant in the era of active surveillance. We submit that lymph node metastases in GS6 cancer be used as a proxy for adherence to the 2005 ISUP consensus on Gleason grading.

AB - Based on revisions of Gleason scoring in 2005, it has been reported that nodal metastases at radical prostatectomy in Gleason 3+3=6 (GS6) prostate cancer are extremely rare, and that GS6 cancers with nodal metastases are invariably upgraded upon review by academic urological pathologists. We analysed the prevalence and determinants of nodal metastases in a national sample of patients with GS6 cancer. We utilised the SEER database to identify patients diagnosed with GS6 prostate cancer during 2004-2010 who had radical prostatectomy and ≥1 lymph node(s) examined. We calculated the prevalence of nodal metastases and constructed a multivariable logistic regression model to identify factors associated with nodal metastases. Among 21,960 patients, the prevalence of nodal metastases was 0.48%. Older age, preoperative PSA ≥10 ng/mL, and advanced stage were positively associated with nodal metastases. Lymph node metastases in GS6 cancer are more prevalent in a nationwide population compared to academic centres. Revised guidelines for Gleason scoring have made GS6 cancer a more homogeneously indolent disease, which may be relevant in the era of active surveillance. We submit that lymph node metastases in GS6 cancer be used as a proxy for adherence to the 2005 ISUP consensus on Gleason grading.

KW - Gleason score

KW - Lymph node metastasis

KW - Prostatic neoplasms

KW - SEER program

UR - http://www.scopus.com/inward/record.url?scp=84902191107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902191107&partnerID=8YFLogxK

U2 - 10.1097/PAT.0000000000000097

DO - 10.1097/PAT.0000000000000097

M3 - Article

C2 - 24798166

AN - SCOPUS:84902191107

VL - 46

SP - 306

EP - 310

JO - Pathology

JF - Pathology

SN - 0031-3025

IS - 4

ER -